PBC-transplantation and disease recurrence

Area of Science:

• Hepatology
• Immunology
• Transplant Surgery

Background:

• Primary biliary cholangitis (PBC) is an autoimmune liver disease where ursodeoxycholic acid (UDCA) is standard therapy.
• Despite UDCA, some patients progress to liver transplant (LT) or death, experiencing symptoms like pruritus and fatigue.
• PBC presents unique challenges including pre-cirrhotic portal hypertension, hepatocellular carcinoma (HCC) risk, and higher waiting list mortality compared to PSC.

Purpose of the Study:

• To review the clinical course, prognostic factors, and outcomes of liver transplantation (LT) in patients with primary biliary cholangitis (PBC).
• To discuss the management of symptoms, complications like HCC, and post-LT outcomes including recurrence and survival.
• To highlight the role of UDCA and potential biomarkers in managing PBC post-LT.

Main Methods:

• Review of existing literature on PBC, its progression, prognostic models (MELD, Mayo risk score), and LT outcomes.
• Analysis of data concerning symptom management, HCC incidence and risk factors, and waiting list mortality.
• Examination of post-LT complications such as rejection and recurrence, and the impact of immunosuppression and UDCA therapy.

Main Results:

• Liver transplantation is effective for pruritus in PBC, but fatigue often persists. Pre-cirrhotic portal hypertension and HCC are significant concerns.
• PBC patients face higher waiting list mortality than PSC patients. While hyperlipidemia is common, cardiovascular risk is not elevated.
• Post-LT, PBC patients experience higher rates of acute and late cellular rejection. Five-year survival post-LT is 80-85%. Recurrence rates vary (14-42%), but graft loss is uncommon.

Conclusions:

• Liver transplantation offers good survival for PBC patients, though recurrence and rejection are concerns. Tacrolimus-based immunosuppression is standard.
• Long-term UDCA may reduce PBC recurrence post-LT. Biomarkers are needed to identify at-risk patients for early intervention.
• Further research into biomarkers for PBC recurrence post-LT is crucial for optimizing long-term graft and patient survival.